Multivariable | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Univariable | Model I (Base line PSA adjusted) (n = 52; chi-square 45.5; AIC 229.7) | Model II (n = 52; chi-square 13.2; AIC 234.7) | ||||||||
Factors | Group | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value |
Age | Continuous | 0.99 | 0.95–1.03 | 0.642 | ||||||
ECOG-PS | 1 vs 0 | 1.13 | 0.40–3.17 | 0.820 | ||||||
Log-transformed baseline PSA level (ng/dL) | Continuous | 1.14 | 0.95–1.36 | 0.156 | 3.62 | 1.57–8.36 | 0.003 | |||
Baseline Hb level (g/dl) | Low vs normal | 3.31 | 1.68–6.51 | 0.001 | ||||||
Baseline ALP level (IU/l) | High vs normal | 1.58 | 0.84–2.972 | 0.157 | ||||||
Baseline LDH level (IU/l) | High vs normal | 1.23 | 0.66–2.29 | 0.510 | ||||||
Presence of bone pain | Yes vs No | 1.52 | 0.81–2.84 | 0.191 | ||||||
Biopsy Gleason score | ≥8 vs ≤7 | 2.60 | 0.62–10.82 | 0.190 | ||||||
Visceral metastasis | Yes vs No | 28.62 | 4.03–203.21 | 0.001 | ||||||
EOD score | ≥3 vs ≤2 | 3.89 | 1.91–7.92 | <0.001 | 3.14 | 1.45–6.82 | 0.004 | 3.47 | 1.65–7.33 | 0.001 |
Sub-group in the CHAARTED trial | high vs low | 2.44 | 1.28–4.65 | 0.007 | ||||||
Log-transformed PSA change (baseline-12wks) | Continuous | 1.10 | 0.92–1.32 | 0.281 | 0.30 | 0.13–0.68 | 0.004 | 1.04 | 0.87–1.25 | 0.66 |
Hb level at 12 weeks | Low vs normal | 1.94 | 1.02–3.67 | 0.043 | ||||||
ALP level at 12 weeks | High vs normal | 3.19 | 1.67–6.11 | 0.001 | ||||||
LDH level at 12 weeks | High vs normal | 1.17 | 0.59–2.31 | 0.652 |